HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Dutta, S. Articles by Fishman, D. A. PubMed PubMed Citation Articles by Dutta, S. Articles by Fishman, D. A. Social Bookmarking                      What's this? Hotlight (NEW!) What's Hotlight?

New Frontiers for Ovarian Cancer Risk Evaluation: Proteomics and Contrast-Enhanced Ultrasound

¹ Department of Obstetrics, Gynecology, and Reproductive Sciences, Mount Sinai School of Medicine, 1176 Fifth Ave., Box 1170, New York, NY 10029.
² Present address: Department of Radiology, Vanderbilt University Medical Center, Nashville, TN.

Abstract

OBJECTIVE. The grim ovarian cancer statistics are attributed to the fact that most women typically present with widespread disease at the time of initial diagnosis. Our current diagnostic tools, such as pelvic examination and standard ultrasound, are inadequate to detect early-stage epithelial ovarian cancer. In recent years there has been an explosion of important advances in biomedical engineering, proteomic technologies, and computational analyses that has led to the identification of hundreds of previously unknown proteins unique to the pathophysiology of ovarian cancer, some of which are currently under clinical validation. At present, no one biomarker exists with 100% specificity and sensitivity for the accurate detection of early-stage epithelial ovarian cancer.

CONCLUSION. As the search for a panel of biomarkers detecting cancer, let alone early-stage disease, progresses, diagnostic imaging will continue to play a critical role to confirm or refute these biomarker assays. Interestingly, recent studies using contrast-enhanced ultrasound have shown potential as an early-detection tool by detecting the aberrant vascularity required for tumor growth before the development of a mass. Thus, we propose that the use of proteomic-based biomarker discovery and contrast-enhanced ultrasound may serve as a promising combination to help accurately identify early-stage epithelial ovarian cancer to improve women's health care.

Keywords: CA-125 • contrast-enhanced ultrasound • early detection • ovarian cancer • proteomics • serum biomarkers

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. J. Pickhardt and M. E. Hanson Incidental Adnexal Masses Detected at Low-Dose Unenhanced CT in Asymptomatic Women Age 50 and Older: Implications for Clinical Management and Ovarian Cancer Screening Radiology, July 27, 2010; (2010) radiol.10100511v1. [Abstract] [Full Text]